Abstract
dc:descriptionThis quality improvement project looks at Sugammadex dosing regimens in a facility that uses qualitative assessment to assess neuromuscular recovery. To determine how dosing of Sugammadex impacts residual paralysis three dosing groups will be compared, the facility standard dosing regime of 200 mg, the manufacture recommended 2mg/kg and what recent literature recommends 1mg/kg. To determine residual paralysis tidal volume and negative inspiratory flow will be measured. This quality improvement project has the potential to reduce incidences of residual paralysis in facilities using qualitative assessment.
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Cantu, Ashlea C. (Ashlea Catherine)
- Caron, Eric A.
- Laginess, Michelle L. (Michelle Lynn)
- Contributors dc:contributor
-
- Lourens, Gayle
Subjects
dc:subject × 3Rights
dc:rights- Statement dc:rights
-
- In Copyright
- Language dc:language
- English
Identifiers
dc:identifier.*- Identifier
-
dnp:42
oclc:1378907438
local:R_e5v1Jmgt34Psb17 - OAI identifier oai:identifier
- oai:d.lib.msu.edu:dnp_42